|
|
Anti-IL-5 Nanobody Screening and Activity Detection |
LI Shijie1,DAI Weiyan2,WANG Xuelian2,LIU Chang2,LIANG Yaoji2,BAI Zhonghu1,**(),CHEN Yongqi2,**() |
1 National Engineering Laboratory of Cereal Fermentation Technology, Jiangnan University, Wuxi 214122, China 2 Zhuhai Resproly Pharmaceutical Technology Co., Ltd, Zhuhai 519040, China |
|
|
Abstract Interleukin-5 (IL-5), a homodimeric cytokine, is an important regulator of eosinophil (EOS) proliferation, activation and maturation. Anti-IL-5 monoclonal antibodies block the binding of IL-5 to the IL-5 receptor subunit alpha (IL-5Rα) and have been used successfully in the treatment of eosinophilic asthma. Currently available monoclonal antibody drugs require repeated administration by injection, which has a significant impact on patient compliance, and the systemic exposure rate of injection is high. To obtain nanobodies suitable for inhalation administration, monoclonal clones were selected through three rounds of panning in the natural alpaca library by phage ELISA screening. A total of 461 positive clones were obtained, of which 50 clone sequences were unique, and 30 molecules were selected for recombinant expression and purification of nanobodies. The in vitro activity of the candidate antibodies was tested by ELISA binding, ELISA blocking, FACS blocking and TF-1 proliferation inhibition assays, and a nanobody AIL-A96-Fc with the ability to block the binding of IL-5 and IL-5Rα was successfully obtained. ELISA binding assays with human and cynomolgus IL-5 showed that the molecule has good human-cynomolgus cross-species activity, and AIL-A96-Fc showed good blocking effects in FACS and ELISA blocking assays. This study not only provides a candidate nanobody (AIL-A96-Fc), but the development methodology also provides guidance for the subsequent development of additional candidate nanobodies targeting IL-5.
|
Received: 27 July 2023
Published: 03 April 2024
|
|
|
|
[1] |
Perkins T N, Oczypok E A, Dutz R E, et al. The receptor for advanced glycation end products is a critical mediator of type 2 cytokine signaling in the lungs. Journal of Allergy and Clinical Immunology, 2019, 144(3): 796-808.e12.
doi: 10.1016/j.jaci.2019.03.019
|
|
|
[2] |
Drick N, Milger K, Seeliger B, et al. Switch from IL-5 to IL-5-receptor α antibody treatment in severe eosinophilic asthma. Journal of Asthma and Allergy, 2020, 13: 605-614.
doi: 10.2147/JAA.S270298
pmid: 33204117
|
|
|
[3] |
Zhu M J, Yang J, Chen Y F. Efficacy and safety of treatment with benralizumab for eosinophilic asthma. International Immunopharmacology, 2022, 111: 109131.
doi: 10.1016/j.intimp.2022.109131
|
|
|
[4] |
Busse W W, Viswanathan R. What has been learned by cytokine targeting of asthma? Journal of Allergy and Clinical Immunology, 2022, 150(2): 235-249.
doi: 10.1016/j.jaci.2022.06.010
|
|
|
[5] |
Clutterbuck E J, Hirst E M, Sanderson C J. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood, 1989, 73(6): 1504-1512.
pmid: 2653458
|
|
|
[6] |
Pelaia C, Paoletti G, Puggioni F, et al. Interleukin-5 in the pathophysiology of severe asthma. Frontiers in Physiology, 2019, 10: 1514.
doi: 10.3389/fphys.2019.01514
pmid: 31920718
|
|
|
[7] |
Yang Z L, Li C, Song Y L, et al. Inhalable antibodies for the treatment of COVID-19. Innovation [Cambridge (Mass)], 2022, 3(6): 100328.
|
|
|
[8] |
Lai S K, McSweeney M D, Pickles R J. Learning from past failures: challenges with monoclonal antibody therapies for COVID-19. Journal of Controlled Release, 2021, 329: 87-95.
doi: 10.1016/j.jconrel.2020.11.057
pmid: 33276017
|
|
|
[9] |
Bianco F, Salomone F, Milesi I, et al. Aerosol drug delivery to spontaneously-breathing preterm neonates: lessons learned. Respiratory Research, 2021, 22(1): 71.
|
|
|
[10] |
Li C, Zhan W Q, Yang Z L, et al. Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody. Cell, 2022, 185(8): 1389-1401.e18.
doi: 10.1016/j.cell.2022.03.009
pmid: 35344711
|
|
|
[11] |
Nambulli S, Xiang Y F, Tilston-Lunel N L, et al. Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses. Science Advances, 2021, 7(22): eabh0319.
|
|
|
[12] |
Hoey R J, Eom H, Horn J R. Structure and development of single domain antibodies as modules for therapeutics and diagnostics. Experimental Biology and Medicine, 2019, 244(17): 1568-1576.
doi: 10.1177/1535370219881129
|
|
|
[13] |
Franco E J, Sonneson G J, DeLegge T J, et al. Production and characterization of a genetically engineered anti-caffeine camelid antibody and its use in immunoaffinity chromatography. Journal of Chromatography B, 2010, 878(2): 177-186.
doi: 10.1016/j.jchromb.2009.06.017
pmid: 19560409
|
|
|
[14] |
Goldman E R, Liu J L, Zabetakis D, et al. Enhancing stability of camelid and shark single domain antibodies: an overview. Frontiers in Immunology, 2017, 8: 865.
doi: 10.3389/fimmu.2017.00865
pmid: 28791022
|
|
|
[15] |
谢秋玲, 罗美华, 雷云, 等. VEGF纳米抗体的筛选、表达及特异性检测. 华南理工大学学报, 2020, 48(9):141-147.
|
|
|
[15] |
Xie Q L, Luo M H, Lei Y, et al. Screening, expression and specificity detection of anti-VEGF nanobodies. Journal of South China University of Technology, 2020, 48(9):141-147.
|
|
|
[16] |
蔺士新, 刘东晨, 雷云, 等. TNF-α纳米抗体的筛选、表达及特异性检测. 中国生物工程杂志, 2020, 40(7): 15-21.
|
|
|
[16] |
Lin S X, Liu D C, Lei Y, et al. Screening, expression and specificity detection of anti-TNF-α nanobody. China Biotechnology, 2020, 40(7): 15-21.
|
|
|
[17] |
Revier M D, Geng B. Mepolizumab prefilled syringe for the treatment of severe eosinophilic asthma: focus on the pediatric population. Expert Review of Respiratory Medicine, 2022, 16(8): 857-865.
doi: 10.1080/17476348.2022.2109465
|
|
|
[18] |
Hashimoto S, Kroes J A, Eger K A, et al. Real-world effectiveness of reslizumab in patients with severe eosinophilic asthma-first initiators and switchers. The Journal of Allergy and Clinical Immunology: in Practice, 2022, 10(8): 2099-2108.e6.
doi: 10.1016/j.jaip.2022.04.014
|
|
|
[19] |
Enríquez-Rodríguez A I, Hermida Valverde T, Romero Álvarez P, et al. Results in clinical practice in the treatment of severe eosinophilic asthma with mepolizumab: a real-life study. The Journal of Asthma, 2022, 59(5): 1005-1011.
doi: 10.1080/02770903.2021.1897835
|
|
|
[20] |
García-Moguel I, Rosado A, Gómez-Cardeñosa A, et al. Reliability, satisfaction and effectiveness of benralizumab home self-administration in patients with severe eosinophilic asthma in real-world practice: the auto-benra study. Journal of Asthma and Allergy, 2022, 15: 623-632.
doi: 10.2147/JAA.S358738
pmid: 35592384
|
|
|
[21] |
Barbarot N, Nourry E, Massart N, et al. Treating acute severe eosinophilic asthma with IL-5 inhibitors in ICU. Case Reports in Pulmonology, 2022, 2022: 2180795.
|
|
|
[22] |
Patino E, Kotzsch A, Saremba S, et al. Structure analysis of the IL-5 ligand-receptor complex reveals a wrench-like architecture for IL-5Rα. Structure, 2011, 19(12): 1864-1875.
doi: 10.1016/j.str.2011.08.015
pmid: 22153509
|
|
|
[23] |
Van Heeke G, Allosery K, De Brabandere V, et al. Nanobodies® as inhaled biotherapeutics for lung diseases. Pharmacology & Therapeutics, 2017, 169: 47-56.
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|